Retatrutide Reverses Fatty Liver & Visceral Fat Fast!

3 Aug 2026 · 1 min

Watch on YouTube

0:40

In this brief monologue, the speaker explains that retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. They cite studies indicating up to an 80% reduction in fatty liver and direct visceral fat loss, noting that the drug suppresses appetite, enhances fat burning, and uniquely maintains or even raises metabolic rate during caloric deficit. The speaker predicts imminent FDA approval for diabetes, knee osteoarthritis, and obesity, while also observing that the drug is already being accessed and promoted widely outside formal channels.

Chapters

Now, retatrutide is a triple agonist, GLP-1, GIP, and glucagon receptor agonist. Studies have shown up to an 80% reduction in fatty liver and direct visceral fat loss with retatrutide. It effectively blunts your appetite, improves fat burning, and maintains and actually increases metabolic rate even while in a caloric deficit, which was almost unheard of until now. Retatrutide is about to hit the market as an FDA-approved treatment for probably diabetes, probably knee osteoarthritis. Arthritis, and obesity. But again, people have gotten their hands on it all over the place and are shouting its benefits from the rooftops.